(Q38203823)

31 August 2017

title

Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations (English)

1 reference

31 August 2017

1 reference

1 reference

1 reference

1 reference

Clara T M M de Kanter

1

1 reference

31 August 2017

Joost P H Drenth

2

1 reference

31 August 2017

Joop E Arends

3

1 reference

31 August 2017

Henk W Reesink

4

1 reference

31 August 2017

Marc van der Valk

5

1 reference

31 August 2017

Robert J de Knegt

6

1 reference

31 August 2017

David M Burger

7

1 reference

31 August 2017

publication date

1 May 2014

1 reference

Clinical Pharmacokinetics

31 August 2017

published in

1 reference

31 August 2017

volume

53

1 reference

31 August 2017

issue

5

1 reference

31 August 2017

page(s)

409-427

1 reference

Evolving epidemiology of hepatitis C virus

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

The natural history of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

21 January 2018

Viruses and interferons

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Hepatitis C virus: virology and life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Review article: pegylated interferons: chemical and clinical differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pharmacokinetics of pegylated interferons: what is misleading?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Effect of dietary purines on the pharmacokinetics of orally administered ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Characterization of ribavirin uptake systems in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Telaprevir: pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Structure, biology, and therapeutic implications of pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Equal efficacy between the two types of peginterferon on HCV: a matter of relapse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Review and management of drug interactions with boceprevir and telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

The importance of drug-drug interactions in the DAA era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

HIV and viral hepatitis coinfections: advances and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Current and future therapies for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0142-5

Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function

21 January 2018

1 reference

12 December 2020

Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

1 reference

12 December 2020

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.

1 reference

12 December 2020

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

12 December 2020

Pegylation of interferon alfa: structural and pharmacokinetic properties

1 reference

12 December 2020

Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.

1 reference

12 December 2020

Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1

1 reference

12 December 2020

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

12 December 2020

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

12 December 2020

The clinical pharmacology of ribavirin

1 reference

12 December 2020

In vivo interferon system assessed by 2'-5' oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin

1 reference

12 December 2020

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial

1 reference

12 December 2020

CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy.

1 reference

12 December 2020

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

12 December 2020

Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study

1 reference

12 December 2020

The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

1 reference

12 December 2020

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

12 December 2020

Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.

1 reference

12 December 2020

10.1007/S40262-014-0142-5

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1005453283

0 references

1 reference